Prosight Management LP Has $3.24 Million Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Prosight Management LP trimmed its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 22.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,000 shares of the company's stock after selling 20,000 shares during the period. LivaNova accounts for approximately 0.9% of Prosight Management LP's holdings, making the stock its 26th largest position. Prosight Management LP owned about 0.13% of LivaNova worth $3,242,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. KBC Group NV lifted its stake in shares of LivaNova by 130.5% in the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock worth $4,628,000 after buying an additional 56,580 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after buying an additional 1,424 shares in the last quarter. Rhumbline Advisers boosted its holdings in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in LivaNova during the fourth quarter worth $2,772,000. Finally, Envestnet Asset Management Inc. boosted its position in LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after buying an additional 5,850 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on LIVN. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Stifel Nicolaus lowered their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a report on Tuesday. Finally, The Goldman Sachs Group decreased their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $59.29.

LivaNova Price Performance

Shares of LIVN traded up $1.03 during midday trading on Tuesday, hitting $45.00. The company's stock had a trading volume of 244,967 shares, compared to its average volume of 735,721. The company's fifty day simple moving average is $38.49 and its two-hundred day simple moving average is $44.76. LivaNova PLC has a one year low of $32.48 and a one year high of $61.94. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of 107.11 and a beta of 0.84.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.